voriconazolo hameln
hameln pharma gmbh - voriconazolo - voriconazolo
daktarin mundgel gel orale
jntl consumer health ii (switzerland) gmbh - miconazolum - gel orale - miconazolum 20 mg, sono, saccharinum natricum, excipiens annuncio gelatum pro 1 g corrisp. ethanolum 1 % v/v. - antifungini - synthetika
sporanox soluzione orale
janssen-cilag ag - itraconazolum - soluzione orale - itraconazolum 100 mg, hydroxypropylbetadexum 4 g, acidum hydrochloridum concentratum, propylenglycolum 1.04 g, natrii hydroxidum ad ph, sorbitolum liquidum non cristallisabile corresp. sorbitolum 1981 mg, aromatica (kirsche), ethanolum 0.05 mg, saccharinum natricum, saccharum tostum, aqua purificata ad solutionem pro 10 ml corresp. natrium 5.38 mg. - antifungini - synthetika
itraconazol zentiva capsule
helvepharm ag - itraconazolum - capsule - itraconazolum 100 mg, sacchari sphaerae corresp. saccharum 180 mg, hypromellosum, sorbitani stearas, silica colloidalis hydrica, kapselhülle: gelatina, e 171, e 172 (rubrum), excipiens pro capsula. - antifungini - synthetika
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - agenti antineoplastici - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
itraconazolo doc generici
doc generici srl - itraconazolo - itraconazolo
sevoflurane piramal
piramal critical care b.v. - sevoflurano - sevoflurano
flucostenol 50mg capsule rigide
sofar - fluconazolo - capsule rigide - 50 mg - antimicotici per uso sistemico, derivati triazolici - trattamento di: criptococcosi, candidiasi sistemiche, candidiasi delle mucose, candidiasi genitale, infezioni micotiche nei pazienti immunocompromessi, dermatomicosi, micosi endemiche profonde. per le informazioni dettagliate consultare il foglio illustrativo.